Aptamer Sciences Inc
Aptamer Sciences Inc has a liquidity position characterized by a current ratio of 2.2, indicating a strong ability to meet short-term obligations, supported by cash and equivalents of KRW 21,376,249,240. However, the company's operating cash flow is negative at KRW -9,670,487,370, and free cash flow is also negative at KRW -7,530,592,040, suggesting ongoing cash outflows from operations. Profitability metrics show significant underperformance relative to industry norms. The company's return on equity is -0.3054 and return on assets is -0.2097, both indicating substantial losses relative to equity and total assets. These figures are well below the typical performance of companies in the Biotechnology & Medical Research industry. The company's revenue is concentrated in a few segments, with disclosed services in aptamer synthesis and discovery, and product development in biopharmaceuticals and diagnostic kits. There is no detailed breakdown of geographic revenue distribution in the provided data, but the company is based in Korea, suggesting a potential regional concentration. Aptamer Sciences Inc is currently experiencing a negative growth trajectory, with significant operating and net losses. The company's financial outlook for the current fiscal year is not explicitly provided, but the negative operating and net income figures suggest a challenging period ahead. The company's capital expenditures are relatively low at KRW -20,489,580, indicating minimal investment in new assets. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio is 0.27, suggesting a conservative capital structure with limited leverage. There are no indications of dilution potential in the basic shares outstanding, as both basic and diluted shares are the same at 40,257,092. Recent events and filings do not show any significant developments that would impact the company's financial position or strategic direction. The company's financial statements and risk assessments do not highlight any major recent events or regulatory actions that would affect its operations or market position.
Business. Aptamer Sciences Inc is a Korea-based company engaged in the research and development of bio therapeutic drugs, providing services such as aptamer synthesis and discovery, and developing biopharmaceuticals including insulin substitutes, insulin sensitizers, and liver cancer drugs, as well as producing lung cancer diagnostic kits.
Classification. Aptamer Sciences Inc is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a classification confidence of 0.92.
- Aptamer Sciences Inc has a strong liquidity position with a current ratio of 2.2, but faces significant cash outflows from operations.
- The company's profitability metrics, including return on equity and return on assets, are negative and indicate substantial underperformance.
- Revenue is concentrated in a few segments, with a focus on biopharmaceuticals and diagnostic kits, and the company is based in Korea.
- The company is experiencing a negative growth trajectory with significant operating and net losses, and minimal capital expenditures.
- The risk assessment indicates low liquidity and dilution risk, with a conservative capital structure and no immediate filing-based flags.
- # RATIONALES
- {
- "margin_outlook_rationale": "The company's margin outlook is negative due to significant operating and net losses, indicating poor cost control and revenue generation.",
- No immediate filing-based liquidity or dilution flags were detected.